Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options.
Riccardo BixioDavide BertelleFrancesca PistilloElisa PedrolloAntonio CarlettoMaurizio RossiniOmbretta ViapianaPublished in: Clinical rheumatology (2022)
Although the available evidence remains scarce, we consider glucocorticoids, methotrexate, and rituximab as safe and effective options. The role of tumor-necrosis factor inhibitors remains uncertain. Eventually, Janus Kinase inhibitors are a novel interesting option for these patients. Key Points • To date, the only evidence on the treatment of patients with rheumatoid arthritis and concomitant myasthenia gravis derives from case reports. • Based on the review of the available case reports and on the cases we described, we consider glucocorticoids, methotrexate, and rituximab as safe and effective options, while the role of Tumor-necrosis factor inhibitors remains uncertain. • Based on the cases we described, Janus Kinase inhibitors are a novel interesting option for patients with concomitant rheumatoid arthritis and myasthenia gravis.
Keyphrases
- myasthenia gravis
- rheumatoid arthritis
- disease activity
- end stage renal disease
- case report
- diffuse large b cell lymphoma
- high dose
- ejection fraction
- chronic kidney disease
- newly diagnosed
- ankylosing spondylitis
- prognostic factors
- patient reported outcomes
- hodgkin lymphoma
- chronic lymphocytic leukemia
- low dose
- systemic lupus erythematosus
- patient reported